Advertisement
New Zealand markets close in 3 hours 1 minute
  • NZX 50

    11,693.71
    -42.00 (-0.36%)
     
  • NZD/USD

    0.6102
    -0.0006 (-0.10%)
     
  • NZD/EUR

    0.5616
    -0.0005 (-0.09%)
     
  • ALL ORDS

    8,122.70
    -9.40 (-0.12%)
     
  • ASX 200

    7,850.40
    -13.30 (-0.17%)
     
  • OIL

    79.71
    -0.09 (-0.11%)
     
  • GOLD

    2,431.90
    -6.60 (-0.27%)
     
  • NASDAQ

    18,674.19
    +127.96 (+0.69%)
     
  • FTSE

    8,424.20
    +3.94 (+0.05%)
     
  • Dow Jones

    39,806.77
    -196.82 (-0.49%)
     
  • DAX

    18,768.96
    +64.54 (+0.35%)
     
  • Hang Seng

    19,452.17
    -184.05 (-0.94%)
     
  • NIKKEI 225

    39,176.51
    +106.83 (+0.27%)
     
  • NZD/JPY

    95.4280
    +0.0500 (+0.05%)
     

Is Biogen Inc.'s (NASDAQ:BIIB) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Biogen's (NASDAQ:BIIB) stock is up by a considerable 12% over the past month. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement. Specifically, we decided to study Biogen's ROE in this article.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

See our latest analysis for Biogen

How Do You Calculate Return On Equity?

The formula for return on equity is:

ADVERTISEMENT

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Biogen is:

23% = US$3.1b ÷ US$14b (Based on the trailing twelve months to March 2023).

The 'return' is the income the business earned over the last year. One way to conceptualize this is that for each $1 of shareholders' capital it has, the company made $0.23 in profit.

What Has ROE Got To Do With Earnings Growth?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

Biogen's Earnings Growth And 23% ROE

Firstly, we acknowledge that Biogen has a significantly high ROE. Additionally, a comparison with the average industry ROE of 23% also portrays the company's ROE in a good light. Needless to say, we are quite surprised to see that Biogen's net income shrunk at a rate of 13% over the past five years in spite of its decent. Based on this, we feel that there might be other reasons which haven't been discussed so far in this article that could be hampering the company's growth. Such as, the company pays out a huge portion of its earnings as dividends, or is faced with competitive pressures.

However, when we compared Biogen's growth with the industry we found that while the company's earnings have been shrinking, the industry has seen an earnings growth of 32% in the same period. This is quite worrisome.

past-earnings-growth
past-earnings-growth

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Has the market priced in the future outlook for BIIB? You can find out in our latest intrinsic value infographic research report.

Is Biogen Making Efficient Use Of Its Profits?

Because Biogen doesn't pay any dividends, we infer that it is retaining all of its profits, which is rather perplexing when you consider the fact that there is no earnings growth to show for it. It looks like there might be some other reasons to explain the lack in that respect. For example, the business could be in decline.

Conclusion

Overall, we feel that Biogen certainly does have some positive factors to consider. Yet, the low earnings growth is a bit concerning, especially given that the company has a high rate of return and is reinvesting ma huge portion of its profits. By the looks of it, there could be some other factors, not necessarily in control of the business, that's preventing growth. With that said, we studied the latest analyst forecasts and found that while the company has shrunk its earnings in the past, analysts expect its earnings to grow in the future. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here